Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? J Microbiol Immunol Infect • June 1, 2020
A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. J Microbiol Immunol Infect • May 4, 2020
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect • April 26, 2020
Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect • April 9, 2020April 10, 2020
Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia. J Microbiol Immunol Infect • October 20, 2017
Changing epidemiology of candidemia in a medical center in middle Taiwan. J Microbiol Immunol Infect • February 3, 2016
Employing infectious disease physicians affects clinical and economic outcomes in regional hospitals: evidence from a population-based study. J Microbiol Immunol Infect • March 31, 2015
Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. J Microbiol Immunol Infect • March 3, 2015
Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan. J Microbiol Immunol Infect • June 5, 2013
Prognostic factors of candidemia among nonneutropenic adults with total parenteral nutrition. J Microbiol Immunol Infect • June 6, 2012